63619-84-1

Basic information

• Product Name: Trioxifene
• Synonyms: Trioxifene;[3,4-Dihydro-2-(4-methoxyphenyl)naphthalen-1-yl]4-[2-(1-pyrrolidinyl)ethoxy]phenyl ketone;Trioxifen;(3,4-Dihydro-2-(4-methoxyphenyl)-1-naphthyl)(4-(2-(1-pyrrolidinyl)ethyl)phenyl)keton;3,4-Dihydro-2-(p-methoxyphenyl)-1-naphthyl p-(2-(1-pyrrolidinyl)ethoxy)phenyl)ketone;68307-81-3 (Methanesulfonate);Lilly 88571;Methanone, (3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-
• CAS NO: 63619-84-1
• Molecular Formula: C31H35NO6S
• Molecular Weight: 549.6777
• Mol File: 63619-84-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 633.5°Cat760mmHg
• Flash Point: 336.9°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 5.91E-16mmHg at 25°C
• Refractive Index: 1.613
• CAS DataBase Reference: Trioxifene(CAS DataBase Reference)
• NIST Chemistry Reference: Trioxifene(63619-84-1)
• EPA Substance Registry System: Trioxifene(63619-84-1)

Safety Data

• Hazardous Substances Data: 63619-84-1(Hazardous Substances Data)

Usage

Description

Trioxifene, also known as LY-133,314, is a selective estrogen receptor modulator (SERM) that exhibits competitive binding activity against estradiol for estrogen receptor alpha (ERα) and antagonistic activity against ERα-mediated gene expression. This characteristic makes it a potential therapeutic agent for various medical applications, particularly in the treatment of breast cancer.

Uses

Used in Pharmaceutical Industry:
Trioxifene is used as a therapeutic agent for the treatment of breast cancer. Its selective binding and antagonistic activity against ERα help in modulating the estrogen receptor pathways, which play a crucial role in the growth and progression of breast cancer cells.
Used in Research and Development:
In addition to its clinical applications, Trioxifene is also utilized in research and development for understanding the mechanisms of estrogen receptor interactions and the development of novel therapeutic strategies for hormone-dependent cancers.
Used in Drug Delivery Systems:
Similar to Gallotannin, Trioxifene can also benefit from novel drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. These systems may include organic and metallic nanoparticles as carriers, aiming to improve the overall efficacy of Trioxifene in treating breast cancer and other hormone-dependent conditions.

InChI:InChI=1/C30H31NO3/c1-33-25-13-8-23(9-14-25)28-17-12-22-6-2-3-7-27(22)29(28)30(32)24-10-15-26(16-11-24)34-21-20-31-18-4-5-19-31/h2-3,6-11,13-16H,4-5,12,17-21H2,1H3

Relevant articles and documents

COSMETIC COMPOSITION CONTAINING A NEUROPEPTIDE Y RECEPTOR ANTAGONIST

This invention relates to a cosmetic composition containing at least one NPY-antagonist component mixed with an excipient for cosmetic preparations.